SAB Biotherapeutics (SABS) Added to NASDAQ Biotechnology Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
SAB Biotherapeutics (SABS) Climbs 27% After Reporting SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
December 16, 2021 6:13 AM ESTSAB Biotherapeutics (NASDAQ: SABS) Climbs 27% After Reporting SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
... MoreSAB Biotherapeutics (SABS) Reports SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
December 16, 2021 6:01 AM ESTSAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced data demonstrating that SAB-185, the companys therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in vitro pseudovirus model. The data were generated by scientists at the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER).
These in vitro data demonstrate that SAB-185 retains neutralization activity against the... More
